Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized first-line study of FOLFIRINOX with or without LV5FU2 maintenance versus FIRGEM in metastatic pancreatic adenocarcinoma
2014-002574-36Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Aug 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, fluorouracil, folinic acid, gemcitabine and oxaliplatin in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (3 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Started Aug 2014; status: completed.
02
Drugs
irinotecanfluorouracilfolinic acidgemcitabineoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2014-002574-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002574-36.